Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
352.38M | 348.88M | 321.48M | 267.84M | 258.62M | 248.23M | Gross Profit |
288.54M | 288.81M | 266.84M | 219.53M | 215.33M | 208.90M | EBIT |
53.92M | 58.87M | 37.12M | -24.97M | -5.00M | -44.37M | EBITDA |
54.95M | 64.34M | 40.52M | -10.69M | -1.89M | -45.76M | Net Income Common Stockholders |
40.18M | 42.42M | 67.44M | -30.20M | -10.29M | -49.28M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
106.43M | 104.42M | 82.00M | 65.95M | 87.08M | 95.81M | Total Assets |
270.42M | 263.92M | 239.05M | 171.43M | 187.93M | 202.03M | Total Debt |
18.66M | 18.83M | 48.10M | 48.59M | 48.13M | 47.70M | Net Debt |
-87.77M | -85.59M | -33.90M | -17.36M | -38.96M | -48.12M | Total Liabilities |
67.64M | 70.81M | 96.33M | 189.42M | 187.85M | 202.18M | Stockholders Equity |
202.78M | 193.11M | 142.72M | -17.99M | 82.00K | -150.00K |
Cash Flow | Free Cash Flow | ||||
68.32M | 64.52M | 24.79M | -20.58M | -5.45M | -34.82M | Operating Cash Flow |
67.55M | 66.20M | 26.77M | -17.89M | -1.98M | -30.26M | Investing Cash Flow |
-3.96M | -9.58M | -2.15M | -2.66M | -3.40M | -4.55M | Financing Cash Flow |
-3.61M | -34.20M | -8.57M | -580.00K | -3.35M | 61.56M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | $979.27M | 24.58 | 22.29% | ― | 5.34% | -50.52% | |
57 Neutral | $949.84M | ― | -36.26% | ― | 127.33% | 21.31% | |
53 Neutral | $5.14B | 3.23 | -45.01% | 2.85% | 17.55% | -0.69% | |
50 Neutral | $1.31B | ― | -188.03% | ― | -11.42% | 0.26% | |
50 Neutral | $1.35B | ― | -23.20% | ― | 24.49% | 5.14% | |
47 Neutral | $1.16B | ― | -57.19% | ― | -0.33% | -3.59% | |
39 Underperform | $594.40M | ― | -51.85% | ― | 11070.12% | 32.07% |
MiMedx Group announced its participation in the Bank of America Securities 2025 Healthcare Conference, highlighting its updated investor presentation. The company is poised for growth with expectations of expanding its product portfolio and increasing its presence in surgical settings, driven by favorable market trends and innovative placental-derived products. The announcement underscores MiMedx’s strategic focus on expanding its global footprint and enhancing its product offerings to drive profitability and stakeholder value.
The most recent analyst rating on (MDXG) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MiMedx Group stock, see the MDXG Stock Forecast page.
On April 30, 2025, MiMedx Group announced its first quarter financial results, reporting net sales of $88 million, a 4% increase year-over-year, driven by significant growth in surgical products. Despite a decline in wound product sales and a decrease in gross margin, the company maintained a strong adjusted EBITDA margin of 20%. CEO Joseph H. Capper highlighted the company’s strategic efforts to address challenges in the Medicare landscape and expand their product pipeline, including the introduction of CELERA™. MiMedx remains focused on long-term growth, expecting high single-digit sales growth for 2025 and low double-digit growth in subsequent years.